业绩简评2025 年8 月18 日公司发布2025H1 业绩公告，公司25H1 实现收入9.50 亿元，其中商业销售总额3.10 亿元（佳泰莱占比97.6%），净亏损1.45 亿。经营分析商业化元年，销售迎来起量。公司目前已有佳泰莱（TROP2 ADC）、科泰莱（PD-L1 单抗）、达泰莱（西妥昔单抗）3 款产品获批上市；业务已覆盖30 个省份、300 余个地级市以及2000 余家医院。佳泰莱、...
Source Link业绩简评2025 年8 月18 日公司发布2025H1 业绩公告，公司25H1 实现收入9.50 亿元，其中商业销售总额3.10 亿元（佳泰莱占比97.6%），净亏损1.45 亿。经营分析商业化元年，销售迎来起量。公司目前已有佳泰莱（TROP2 ADC）、科泰莱（PD-L1 单抗）、达泰莱（西妥昔单抗）3 款产品获批上市；业务已覆盖30 个省份、300 余个地级市以及2000 余家医院。佳泰莱、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.